X4 Pharmaceuticals, Inc — Investor Relations & Filings
Filings indexed
784
across all filing types
Latest filing
2026-05-12
Regulatory Filings
Country
US
United States of America
Listing
US
XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | |
| S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45339551 | 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | ||
| 42006962 | S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 41806531 | 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 32999251 | ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999249 | DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999239 | DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32963514 | 10-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-17 | English | ||
| 30181392 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181257 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181249 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181231 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 30181103 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 30181313 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 30181211 | SCHEDULE 13G/A Filing | 2026-01-15 | English | ||
| 12390315 | FORM 4 | 2026-01-07 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Abbott Laboratories (Pakistan) Limited
Manufactures and markets diverse healthcare products: pharm…
|
ABOT | PK | Manufacturing |
|
AbbVie Inc.
A research-based biopharmaceutical company developing and m…
|
ABBV | US | Manufacturing |
|
AbCellera Biologics Inc.
Discovers and develops antibody-based therapeutics using a …
|
ABCL | CA | Manufacturing |
|
AbClon Inc.
Develops antibody-based therapeutics using CAR-T, NEST, and…
|
174900 | KR | Manufacturing |
|
ABEONA THERAPEUTICS INC.
A clinical-stage biopharma developing cell and gene therapi…
|
ABEO | US | Manufacturing |
|
ABINGDON HEALTH PLC
A CDMO specializing in lateral flow assays, offering develo…
|
ABDX | GB | Manufacturing |
|
ABIONYX Pharma
Develops biotherapies and drug delivery vectors using apoli…
|
ABNX | FR | Manufacturing |
|
ABIVAX
Clinical-stage biotech developing therapeutics for chronic …
|
ABVX | FR | Manufacturing |
|
Abivax S.A.
Clinical-stage biotech developing miRNA therapeutics for in…
|
ABVX | US | Manufacturing |
|
ABL Diagnostics
Develops molecular diagnostic solutions for managing infect…
|
ABLD | FR | Manufacturing |
X4 Pharmaceuticals, Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34355/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34355 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34355 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34355 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34355}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for X4 Pharmaceuticals, Inc (id: 34355)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.